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Plasticity of kidney cells: Role in kidney remodeling and scar-
ring. The progression of renal scarring and the associated loss
of function remains one of the main challenges in nephrology.
Until recently, the glomerular and tubulointerstitial scarring
processes were thought to involve primarily interactions be-
tween infiltrating inflammatory cells and resident renal cells
culminating in loss of renal cells and their replacement by
extracellular collagenous matrix (ECM). This review focuses
on new aspects of renal response to injury and remodeling.
Emphasis is on the plasticity of renal cells with the capacity
of both glomerular and tubular cells to assume a range of
phenotypes during the remodeling process. Both glomerular
and tubular epithelial cells regress to primitive/embryonic mes-
enchymal phenotype in response to injury. This reverse em-
bryogenesis is a key step in renal healing and scarring. In
addition to the plasticity of intrinsic renal cells, it is becoming
apparent that renal remodeling in health and disease involves
the migration of progenitor hematopoietic stem cells into the
kidneys. These cells assume various glomerular and tubular
epithelial phenotype. They are also involved in the evolution
of lesions toward healing or scarring. A better understanding
of some of these key events in renal remodeling and their
mediators may open the way to new interventions based on
their manipulations and aimed at favoring renal healing and
preventing scarring.
Worldwide, an increasing number of patients with
chronic kidney diseases progress to end-stage renal fail-
ure (ESRF) every year. It is predicted that this trend
will continue unabated for at least another 10 years [1].
Considerable advancements have been achieved over
the last 25 years in our understanding of the mechanisms
underlying the progression of chronic kidney failure [2].
This has been translated into considerable progress in
the management of patients with progressive chronic kid-
ney disease with raised expectations regarding the slow-
ing, and even halting, of the progression of the underly-
ing nephropathy [3]. However, despite such an optimistic
outlook, more research is needed to define the nature
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of the kidney response to injury and the determinants
of the evolution of the kidney remodeling process toward
healing or scarring. In addition, while progress has been
made in slowing the progression of established nephrop-
athies, very little can so far be done to promote and
accelerate healing and/or reverse established kidney
scarring. For that, a better understanding of the cellular
elements of kidney remodeling is needed to define their
contribution to healing and/or scarring.
This review focuses on the respective contributions to
renal healing and scarring of resident renal cells and
those derived from the bone marrow and their circulating
progeny. Emphasis is on the capacity of resident renal,
glomerular, and tubuloepithelial cells to alter their phe-
notype in response to injury to facilitate healing and/or
contribute to scarring. Special mention is made of the
potential of bone marrow-derived hematopoietic stem
cells (HSCs) to replenish the damaged kidney and thus
contribute to healing and the restoration of tissue integ-
rity. The capacity of these cells, and that of marrow
stromal cells (MSCs), to contribute to renal scarring and
fibrosis is also discussed. A better understanding of the
events regulating cellular behavior in response to renal
injury should, in the foreseeable future, allow the design
of original and innovative interventions based on the
manipulations of kidney cells (intrinsic and extrinsic)
and aimed at promoting healing while preventing and/or
reversing kidney scarring.
MECHANISMS OF KIDNEY SCARRING
Glomerular sclerosis
Current understanding. Advances made over the last
25 years have contributed to our improved understand-
ing of the pathophysiology of progressive glomerular scle-
rosis. In particular, they highlighted important interac-
tions between resident glomerular cells and infiltrating,
mainly inflammatory, cells (reviewed in [2]). Within the
glomeruli, injury is followed by damage to resident cell
lines with as a consequence the release by endothelial cells
of proinflammatory cytokines, chemokines, and growth
factors attracting inflammatory cells to the glomerular
capillaries and initiating a microinflammatory process
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[2]. In addition, the neoexpression by endothelial cells
of adhesion molecules facilitates the adhesion and an-
choring of these cells to the glomerular capillary wall.
Subsequently, the infiltration of the glomerular capillar-
ies by monocytes/macrophages leads to their interaction
with glomerular cells (endothelial, mesangial, and epi-
thelial). These interactions depend on cell-cell contact
and/or the release of chemokines, cytokines, and growth
factors that establish cell-cell communication networks
[4]. Such cross talk between glomerular and infiltrating
cells stimulates the activation, proliferation, and the syn-
thesis of extracellular collagenous matrix (ECM). In-
creased synthesis is often associated with a decreased or
inability to breakdown deposited ECM leading to ir-
reversible glomerular sclerosis. This may be due to inhi-
bition of glomerular collagenases [matrix metallopro-
teinases (MMPs) and plasmin] or the stimulation of their
inhibitors [tissue inhibitors of matrix metalloproteinases
(TIMPs) and plasminogen activator inhibitor-1 (PAI-1)]
(reviewed in [5]). More recently, we have postulated
qualitative changes in ECM cross-linking, mediated by
tissue transglutaminase, that render the kidney ECM
resistant to the proteolytic action of metalloproteinases
[6]. Such resistance to breakdown may prove to be an-
other key factor in the irreversible deposition of ECM
in the course of progressive kidney scarring [6].
Plasticity of glomerular cells in response to injury
Endothelial cells. Recent experimental data suggest that
the response of glomerular cells to injury is more com-
plex, involving considerable phenotypic adaptations. For
instance, endothelial cells once injured transiently lose
their mature anticoagulant, anti-inflammatory, and anti-
proliferative phenotype and acquire new procoagulant,
proinflammatory, and mitogenic characteristics (reviewed
in [7]). This leads to the release of a wide range of chemo-
kines, cytokines, and growth factors that attract plate-
lets and inflammatory cells. The endothelial phenotypic
changes also involve changes in the cell surface proper-
ties of these cells with a switch from a nonadhesive, pro-
tective, and anticoagulant surface to an adhesive one,
facilitating platelets and leukocytes adhesion (reviewed
in [7]).
An important factor in the loss of glomerular endothe-
lial anticoagulant and anti-inflammatory properties may
be the decreased nitric oxide synthase (NOS) activity of
damaged endothelium. Nitric oxide radicals normally
generated by glomerular endothelial cells are involved
in the regulation of the glomerular vascular tone as well
as the inhibition of platelet aggregation. The loss of nitric
oxide–mediated anticoagulant properties would contrib-
ute to the adhesion and aggregation of platelets within
the damaged glomeruli of experimental animals and hu-
mans. Nitric oxide also inhibits leukocyte adhesion to
the glomerular capillaries and thus has anti-inflammatory
effects (reviewed in [8]). The loss of such a protective
factor along with the expression of cell adhesion mole-
cules would facilitate the infiltration of glomerular capil-
laries by inflammatory cells (reviewed in [8]). Of rele-
vance, NOS knockout mice have an accelerated form of
nephrotoxic serum nephritis with increased glomerular
thrombi formation and neutrophil infiltration (reviewed
in [8]). Similarly, the pharmacologic inhibition of nitric
oxide synthesis accelerates the progression of glomerulo-
sclerosis in the rat remnant kidney model [9].
Nitric oxide deficiency may also impair the recovery
of glomerular endothelial cells as it has been associated
with apoptosis and changes in the angiogenic vascular
endothelial growth factor (VEGF) [9]. Following glo-
merular injury, the regeneration of the glomerular capil-
lary endothelium is likely to rely on VEGF-mediated
angiogenesis (reviewed in [10]). VEGF is thought to
mediate reactive endothelial proliferation in damaged
glomeruli. Impaired glomerular endothelial angiogenesis
has been reported after subtotal nephrectomy and impli-
cated in the development of glomerulosclerosis in rem-
nant kidneys (reviewed in [10]). In an experimental
model of glomerulonephritis, the administration of
VEGF165 enhanced glomerular capillary repair and ac-
celerated the resolution of the extensive endothelial
damage (reviewed in [10]).
Mesangial cells. Considerable research has focused on
the phenotypic changes characterizing mesangial cells’
response to activation and injury. Mesangial cells “trans”
or “de”-differentiate in response to injury from a mature,
adult, pericyte-like phenotype (the “mesangiocyte”) to an
embryonic myofibroblastic one (the “mesangioblast”)
characterized by proliferation and contraction. This is
associated with the expression by activated mesangio-
blasts of a range of cytoskeletal proteins including
-smooth muscle actin (-SMA) [11, 12]. This mesangio-
blastic phenotype has been described in experimental
and clinical nephropathies associated with glomerular
proliferative and sclerotic changes [11, 12]. In the anti-
Thy 1 model of mesangiolysis and reparative mesangial
migration and proliferation [13], the expression of mes-
angial -SMA is associated with the glomerular repair
process and the restoration of normal glomerular archi-
tecture [14]. In some respects, the appearance of the
mesangioblasts within glomeruli undergoing repair ap-
pears to reenact the embryologic steps of glomerulo-
genesis [15]. This is supported by the expression by these
cells of CD34 (a 115 kD membrane glycoprotein) [16]
known to be a differentiation antigen expressed on prim-
itive myeloid precursors and in bone MSCs [17]. Mesan-
gial de/transdifferentiation into an embryonic pheno-
type, reverse embryogenesis of adult and mature cells,
aims at healing and the restoration of mesangial integrity.
Changes in mesangial expression of -SMA have been
reported in a wide range of human glomerulopathies
El Nahas: Plasticity of kidney cells 1555
[11, 18]. These are mainly characterized by mesangio-
proliferative glomerulonephritides where -SMA expres-
sion is associated with mesangial proliferation [11, 19].
We have also described similar changes associated with
mesangial proliferation in the course of experimental [20]
and clinical [21] diabetic nephropathy. More recently,
mesangial CD34 expression has also been reported in
human mesangioproliferative glomerulonephritides con-
firming the regression of mesangial cells to an embryonic
mesenchymal phenotype when activated, transformed,
or proliferating [16].
The mesangioblast phenotype is also associated with
changes in the ECM synthetic profile of mesangial cells.
Normally, mature mesangial cells are capable of the syn-
thesis of components of the glomerular ECM, including
collagen IV. On the other hand, the activated mesangio-
blast is capable of releasing interstitial collagens type I
and III not normally detected within healthy/mature glo-
meruli [22]. Such a phenotypic switch can also be induced
by the incubation in culture of mesangial cells with
growth factors such as transforming growth factor-1
(TGF-1) or by the transfection of these cells in vivo
with genes leading to the mesangial overexpression of
this profibrotic growth factor [22]. TGF-1 is believed to
be one of the main growth factors promoting glomerular
sclerosis [23]. The switch from collagen IV to collagens I
and III has major consequences on the progression of
glomerular sclerosis. The glomerular deposition of colla-
gens I and III is irreversible as glomeruli are devoid of
collagenases (MMPs) capable of breaking down such
collagens.
Changes in mesangial phenotype and the subsequent
changes in glomerular ECM profile may also affect mes-
angial cell survival. Mesangial cells 11 integrin expres-
sion appears to be a critical determinant of mesangial
cell phenotype, growth and collagen remodelling capac-
ity [24]. This integrin is a mesangial collagen receptor
implicated in collagen remodeling after injury. Collagen
IV and laminin, the normal constituents of the mesangial
and glomerular ECM have mesangial survival-promoting
properties mediated through a 1 integrin-mediated, but
arg-gly-asp (RGD)-independent, mechanism [25]. On
the other hand, collagen I/III and fibronectin, which are
overexpressed in diseased glomeruli, do not promote
mesangial cell survival, thus potentially contributing to
their apoptosis and depletion during the course of glo-
merular sclerosis [25]. These observations show that mes-
angial cell phenotype and survival are tightly regulated
by changes in the underlying ECM. This implies a vicious
circle of mesangial de/trans-differentiation leading to
qualitative ECM changes, which, in turn, further affect
mesangial phenotype and survival.
The de/trans-differentiation of adult mesangial cells
(mesangiocytes) to embryonic mesangioblasts is charac-
teristic of mesangial response to injury. It leads in some
instances to the repair of glomerular injury through the
migration and proliferation of these cells to restore the
glomerular structural integrity (healing) when the ma-
ture mesangial phenotype is restored [13]. In other in-
stances, continuing mesangioblastic proliferation along
with the synthesis of abnormal ECM is the forerunner
of mesangial and glomerular sclerosis. It is therefore
imperative to further our understanding of the regulators
of mesangial phenotypic changes. Of those, TGF-1 is
likely to play a predmoninant role as this growth factor
is likely to have both beneficial [26] and detrimental [23]
functions. TGF-1 is capable of controlling mesangial
activation, proliferation, and ECM synthesis [23]. It may
play a beneficial role in healing through activation of
mesangial -SMA expression, thus facilitating cellular
contraction and glomerular wound retraction. Its inhibi-
tory effect on mesangial cellular proliferation may con-
trol and complete the healing process [26]. Its apoptotic
effect of mesangial cells may also promote the resolution
of the acute proliferative changes [26]. On the other
hand, TGF-1, with its stimulatory effect on mesangial
synthesis of collagens I and III, may contribute to irre-
versible glomerular sclerosis [23]. This effect of TGF-1
on mesangial phenotype and synthetic capacity is likely
to be mediated by the activation of intracellular signal
transduction pathways involving a range of kinases as
well as a unique set of intracellular proteins called Smads
[27, 28]. Smad6 is up-regulated in the mesangium in
human glomerular diseases and may be involved in func-
tions independent of TGF-/Smad signaling [29]. Smad6
and Smad7 expression in glomerular cells in vivo could
play important roles in cell homeostasis in physiologic
and pathologic conditions [29]. In cultured human mes-
angial cells, the Smads pathway has been implicated in
collagen I synthesis [27, 28]. Smads are also involved in
the stimulation of the basal expression of connective tis-
sue growth factor (CTGF) [30], a key effector of TGF-–
induced fibrogenesis [31]. TGF- also induces mesangial
CTGF through Ras/MEK/ERK kinase pathways [30].
Of interest, the inhibition of Ras/MEK/ERK seems not
to reduce activation/phosphorylation of Smads, sug-
gesting that Smads, although necessary, are insufficient
for TGF- stimulation of the CTGF promoter [30]. Thus,
maximal TGF- induction of CTGF requires synergy
between Smads and Ras/MEK/ERK signaling pathways
[30]. It is therefore expected that the manipulation of
TGF-1–mediated signal transduction pathways within
mesangial cells may in the future prove a fruitful thera-
peutic avenue [27].
Epithelial cells. Glomerular parietal epithelial cells
(GPEC) also response to injury by de/transdifferentia-
tion into a mesenchymal/embryonic phenotype. In these
cells, the de novo expression of -SMA is associated with
the loss of tubuloepithelial markers such as E-cadherin
[32]. At the early stages of glomerular epithelial-mesen-
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chymal trans-differentiation (GEMT), epithelial cells re-
tain their morphology with apical-basal polarity and mi-
crovilli, while ultrastructural studies show the presence
of characteristic intracellular actin microfilaments and
dense bodies [32]. Later in the GEMT process associated
with the parietal epithelial cellular proliferation and cres-
cent formation, large bundles of actin microfilaments are
seen throughout the cell [32]. At this stage, the GPEC
lose their polarity, microvilli, and tight junctions. Glo-
merular parietal epithelial cells respond to injury by
acquiring an embryonic phenotype similar to that of
the mesangioblast/myofibroblast with the expression of
-SMA [32]. These changes are also associated with cres-
cent formation and excessive production of ECM. Cres-
cent formation can also be initiated by injury to the
glomerular visceral epithelial cells [33]. These cells un-
dergo phenotypic alterations characterized by foot pro-
cess effacement and prominent microvillous transforma-
tion [33]. These changes allow the visceral epithelial cells
to spread and form bridges between the glomerular and
parietal basement membranes. These, in turn, stimulate
the proliferation of the GPEC leading to crescent for-
mation [33].
Injury to the glomerular visceral epithelial cells (podo-
cytes) is associated with an up-regulation of TGF-1
[34]. In the remnant kidney model of glomerulosclero-
sis, protein accumulation in podocytes secondary to in-
creased transcapillary passage precedes podocyte de-dif-
ferentiation and is associated with increased TGF-1
expression [34]. Furthermore, albumin loading of podo-
cytes in vitro causes loss of the synaptopodin differentia-
tion marker and the up-regulation of TGF-1 synthesis
[34]. The up-regulation of TGF-1 production by podo-
cytes in response to injury would accelerate the glomeru-
lar sclerosis process. First, TGF-1 would act through
autocrine loops on podocytes to stimulate their synthesis
of ECM. Second, the released TGF-1 would induce a
sclerosing phenotype in adjacent mesangial cells [34].
Third, TGF-1 is capable of inducing the apoptosis of
podocytes, a key step in glomerular cell depletion and
sclerosis [35]. Apoptosis of podocytes is an early event,
preceding mesangial expansion, in the course of the glo-
merulosclerosis observed in mice transgenic to TGF-1
[35]. TGF-1–induced apoptosis of podocytes is p38MAP
kinase and caspase 3 dependent and is potentiated by
the TGF-1 up-regulation of Smad7 [35]. Smad7 is capa-
ble of inducing podocyte apoptosis through the inhibi-
tion of the nuclear translocation of nuclear factor-B
(NF-B), a key cell survival factor [35].
In addition, podocyte phenotypic changes character-
ized by the over- or under-expression of podocyte-associ-
ated proteins such as nephrin, podocin, CD2AP, and
-actinin 4 have all been associated in experimental mod-
els and human nephropathies with heavy proteinuria and
glomerulosclerosis [36].
It is therefore apparent that phenotypic changes char-
acterized by the regression of mature glomerular cells
into an embryonic/mesenchymal phenotype is a feature
of glomerular response to injury (remodeling) with the
excessive production of ECM an undesirable effect that
leads to irreversible fibrosis. In addition, the qualitative
changes in glomerular ECM further destabilize cells
through integrin-mediated signaling, triggering cell death
and apoptosis. Glomerular cell depletion, along with ex-
cessive ECM deposition, is the hallmark of glomerular
sclerosis and obsolescence.
The phenotypic changes affecting glomerular cells
have been labeled trans-differentiation. The term trans-
differentiation is probably misleading as it refers to the
transformation of a mature, epithelial, phenotype into
another. The phenotypic changes described above, in-
volving mesangial and epithelial cells, are more likely to
represent a form of injury-induced de-differentiation/
regression of these cells into a mesenchymal, embryonic,
phenotype reminiscent of the metanephric phenotype
from which they originate [37]. Others have preferred
to describe these events as epithelial mesenchymal tran-
sition or transformation. In fact, the response to injury
of differentiated glomerular cells is, in some ways, a form
of reverse embryogenesis (de-differentiation) followed by
a recapitulated embryogenesis (re-differentiation) lead-
ing to the restoration of glomerular cells maturity and
integrity.
Hematopoietic stem cells: Contribution to healing and
scarring. The presence of glomerular cells with embry-
onic and mesenchymal characteristics during the course
of glomerular remodeling has drawn attention to the
plasticity of glomerular cells and raised questions as to
the origin of some of these cells. The possibility of the
migration into injured glomeruli of hematopoietic pro-
genitor cells suggestive of stem cells has been raised [38].
HSCs are lineage-uncommitted, pluripotent cells, with
the potential to differentiate into a range of nonhemato-
poietic cells [39]. The differentiation of HSCs into organ-
specific cells depends on the microenvironment, niche,
or characteristic of the organ. HSCs are detectable within
the bone marrow as well as in the peripheral blood along
with their progeny [39]. These cells may be involved in
the normal turnover of mesangial cells [40] and in the
response of the mesangium to injury [38]. In rats injected
with an anti-Thy 1 antibody, mesangiolysis is followed
by a steady influx into the glomerular tuft of extraglomer-
ular cells derived from a pool of progenitor cells located
at the vascular pole [13, 38]. Bone marrow transplanta-
tion experiments relying of rats transgenic to the green
fluorescent protein (GFP) demonstrated that up to 12%
of glomerular cells repopulating the glomeruli were de-
rived from the transplanted bone marrow [38]. Bone
marrow–derived Thy 1() cells increased in number un-
til remodeling ceased and they made up 8% of glomeru-
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lar cells [38]. The migration of these cells into injured
glomeruli seems to require platelet-derived growth fac-
tor (PDGF) as well as basic fibroblast growth factor
(bFGF) [41]. While PDGF plays an important role in
the migration of the progenitors cells into the glomeru-
lus, bFGF has been linked to the proliferation of repopu-
lating mesangial cells [41]. This sequence of events is
reminiscent of the role played by PDGF B chain in the
migration of mesangial precursors into nascent glomeruli
during embryogenesis [15]. In embryogenesis, absence
of PDGF B, in PDGF B null mice, leads to a failure of
mesangial cells’ migration into the glomerular tuft and
the formation of collapsing glomeruli with a limited num-
ber of mesangial cells [15]. These observations suggest
that a percentage of mesangial cells involved in the heal-
ing process after acute experimental mesangiolysis are
bone marrow–derived.
Influx of bone marrow–derived progenitor cells into
injured glomeruli may also contribute to the progression
of scarring. Bone marrow transplantation experiments
in rodents have demonstrated that the development of
glomerulosclerosis is dependent on the bone marrow
phenotype rather than that of the kidney itself. When
mice resistant to glomerulosclerosis (ROP /) were
transplanted with bone marrow from glomerulosclerosis-
prone congenic ROP Os/mice, they developed progres-
sive glomerulosclerosis [42]. These observations suggest
that the glomerular sclerosis phenotype may be perpetu-
ated by a continuing influx of bone marrow–derived cells
exhibiting a disease phenotype [42].
Bone marrow–derived progenitor cells may also con-
tribute to the maintenance of a disease phenotype in
conditions characterized by an abnormal mesangial im-
munoglobulin deposition such as IgA nephropathy. Con-
sequently, the transplantation of cells with a normal
phenotype may be therapeutic. In support for such a hy-
pothesis, the transplantation of bone marrow from nor-
mal mice into those producing high circulating IgA levels
and prone to IgA nephropathy (HIGA mice), leads to
a diminution of IgA deposition and the resolution of the
glomerular sclerotic changes [43]. These experimental
data clearly show that beside phenotypic changes of resi-
dent mesangial cells, there is a migration of bone mar-
row–derived hematopoietic precursors into normal as
well as injured glomeruli contributing to their remodel-
ing. Healing may depend on whether these cells acquire a
mature phenotype (adult mesangial cells, mesangiocyte),
while scarring may be due to the persistence of the em-
bryonic phenotype (mesangioblast) with the inherent pro-
pensity to sclerosis.
Bone marrow transplantation and/or that of HSCs
may therefore have a role to play in the treatment of
nephropathies characterized by an abnormal mesangial
phenotype [44, 45]. This will be on the assumption that,
once these cells migrate into diseased glomeruli, they
acquire a healthy adult phenotype [45]. Hematopoietic
cells’ differentiation and maturation within individual
organs appears to depend on the local microenvironment
[39, 46]. This depends on cell-cell and cell-matrix interac-
tions primed by a variety of growth factors [39, 46]. Of
relevance, we have recently reported an up-regulation
of stem cell factor (SCF), a key stem cell chemotactin and
maturation growth factor, in experimental and human
nephropathies [47]. The release by activated glomerular
cells of SCF may therefore by a key factor in the at-
traction and maturation of hematopoietic (c-kit) pro-
genitor cells to the glomeruli during their repair and/or
scarring. Other growth factors, known to affect the traf-
ficking of progenitor cells, such as PDGF and bFGF,
have also been implicated in the pathogenesis of glomer-
ular proliferation and scarring [2]. Whether stem cell
differentiation can be conducted in vitro before the injec-
tion of these cells into recipients with kidney diseases is
subject of speculation [45].
Tubulointerstitial scarring
Current understanding. As with glomerular sclerosis,
it is assumed that the interactions between resident cells
(tubuloepithelial and fibroblastic) and infiltrating in-
flammatory cells (lympho-monocytic) leads to the initia-
tion and progression of tubulointerstitial scarring (re-
viewed in [48]). These interactions have been shown to
be triggered by a variety of stimuli, including proteinuria,
and appear to be mediated by the release by both resi-
dent and infiltrating cells of a variety of chemokines,
cytokines, and growth factors [48].
Plasticity of proximal tubular cells in response to injury.
As with glomerular cells, tubular epithelial cells have
the capacity to regress from an adult, mature, phenotype
to an embryonic/mesenchymal one in response to injuri-
ous stimuli. This so-called epithelial mesenchymal “trans”-
differentiation, or rather, transformation (EMT) has
been reported in response to a variety of growth factors
[TGF-1, epidermal growth factor (EGF) and interleu-
kin-1 (IL-1)] in vitro where the proximal tubular epithe-
lial cells lose their adult phenotype and markers (cyto-
keratins) and acquire myofibroblastic ones such as-SMA
and vimentin [49, 50]. In addition, exposure of proximal
tubule cells to adavanced glycation end products (AGEs)
has also been shown to up-regulate their synthesis of
TGF-1 and induce EMT in vitro [51]. Neutralizing anti-
bodies to the receptor of AGE (RAGE) or to TGF-1,
as well as AGE cross-link breakers, inhibit such EMT
[51]. AGE-induced EMT may underlie the apparent
EMT of tubular epithelial cells of diabetic rats [20, 51].
EMT is associated with the loss of epithelial pheno-
type involving cell hypertrophy, loss of apical-basal po-
larity, and microvilli [49]. Cells become elongated and
invasive forming a new front-end back-end polarity with
appearance of actin microfilaments and dense bodies
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Fig. 1. Process of cell scarring or healing. Ab-
breviations are: TEC, tubuloepithelial cells (prox-
imal tubules cells); TBM, tubular basement
membrane; TGF-1, transforming growth fac-
tor-1; IL-1, interleukin-1; AGE, advanced gly-
cation end product; HGF, hepatocyte growth fac-
tor; MC, mesenchymal cells; -SMA, -smooth
muscle actin; MMP2, matrix metalloprotein-
ase 2; ECM, extracellular matrix; , stimulate;
, inhibit.
[49] (Fig. 1). In addition, experiments using bone marrow
chimeras and transgenic reporter mice showed that a
significant proportion of interstitial fibroblasts express-
ing fibroblast-specific protein 1 (FSP 1) are derived from
local EMT during renal fibrogenesis following unilateral
ureteral obstruction (UUO) [52]. A small number of
FSP 1 fibroblasts appeared to migrate to the renal
interstitial space from the bone marrow [52].
The so-called EMT is merely the regression of the adult
phenotype to the tubular epithelial cell’s embryonic/meta-
nephric mesenchymal one in response to injury. As the
great majority of tubular epithelial cells, including proxi-
mal tubular cells, are derived from the same metanephric
mesenchyme as the renal fibroblasts [37], both cell lines
regress to such an embryonic mesenchymal phenotype
in response to activation and injury. Mature fibroblasts
regress to a myofibroblastic phenotype in response to ac-
tivation with the expression of -SMA, vimentin, and
desmin [53]. This phenotype allows interstitial fibroblasts
to migrate in response to injury and facilitate wound con-
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traction and healing. The appearance and proliferation
of interstitial myofibroblasts is a feature of interstitial
fibrosis in experimental models and clinical nephropa-
thies [18]. We have demonstrated in a wide range of
chronic nephropathies that the number of interstitial my-
ofibroblasts correlates closely with interstitial fibrosis
and is a strong predictor of progressive renal fibrosis and
failure (reviewed in [18]). Myofibroblasts contribute to
interstitial fibrosis through an up-regulation of ECM syn-
thesis (reviewed in [50]).
As with glomerular cellular integrity, the architecture
of the underlying basement membrane appears to play
an important role in the maintenance of tubular epithe-
lial phenotype. Changes in basement membrane archi-
tecture may also lead to the up-regulation of tubular
epithelial release of TGF-1. TGF-1 is thought to be
the most potent promoter of EMT [50]. It was also dem-
onstrated that fibroblast growth factor-2 (FGF-2) made
an important contribution to the mechanisms of EMT
by stimulating microenvironmental proteases (MMPs 2
and 9) essential for basement membrane disintegration,
thus facilitating tubular epithelial cell motility [54].
TGF-1 also stimulates the release of tubular basement
membrane–degrading enzymes such as MMP 2 by tubulo-
epithelial cells [54]. This appears to be a key event in
their EMT and subsequent invasiveness [54]. TGF-1
induction of MMP 2 during EMT appears late (48 hours)
after the initiation of the process and follows the loss of
epithelial adhesion and expression of -SMA [54]. The
degradation of the tubular basement membrane would
facilitate the migration of transformed tubule cells/myo-
fibroblasts into the interstitium. In addition, these cells
have been shown in vitro to have enhanced motility
and invasive capacity [55] (Fig. 1). On the other hand,
hepatocyte growth factor (HGF) has been shown to in-
hibit EMT in the UUO model of renal fibrosis, thus
explaining some of its antifibrotic potentials [56]. HGF
injections blunted the progression of myofibroblast accu-
mulation and collagen deposition [57]. Delayed adminis-
tration of recombinant human HGF, 3 days after the
onset of UUO, was also effective but did not reverse
established interstitial fibrosis [57].
EMT is also likely to be influenced by changes in the
underlying ECM substrate as the behavior of epithelial
cells is strongly influenced, through the action of integ-
rins, by the underlying ECM. Recent experimental data
have shown that type IV collagen contributes to the
maintenance of the epithelial phenotype of proximal tu-
bules epithelial cells, whereas type I collagen promotes
epithelial-to-mesenchymal transformation (EMT) [58].
Experiments demonstrating EMT in vitro have been un-
dertaken with proximal tubules cells cultured on a layer
of collagen type I, an unnatural substrate for tubulo-
epithelial cells [49]. Incubation with recombinant human
1NC1 collagen domain inhibits assembly and deposi-
tion of type IV collagen and facilitates EMT in vitro [58].
Inhibition of type IV collagen assembly by the 1NC1
domain also up-regulates the production of TGF-1 in
proximal tubules epithelial cells, a key growth factor me-
diating EMT [58]. Of note a variety of other stimuli, in-
cluding exposure to albumin, glucose, and lipids, have
been shown to stimulate the release of TGF-1 by proxi-
mal tubules epithelial cells (reviewed in [48]), thus ex-
plaining how proteinuria, glycosuria, and lipiduria may
initiate EMT and subsequent tubulointerstitial fibro-
sis [48].
These observations suggest close interactions between
tubuloepithelial cells and the underlying ECM through
integrin-mediated release of growth factors and metallo-
proteinases. Such interactions, mediated by integrins,
are also required for cells evolution toward survival or
apoptotic pathways [59]. Apoptosis of tubuloepithelial
cells has been implicated in the pathogenesis of kidney
scarring [60]. On the other hand, apoptosis of myofibro-
blasts has been suggested as a mechanism of resolution
of injury toward healing [61]. Failure of myofibroblasts
apoptosis and their continuing proliferation leads to fibro-
sis and scarring [61] (Fig. 1). The observations described
above also demonstrate the possibility that tubuloepithe-
lial cells play an active role in interstitial fibrosis through,
among others, their contribution to the interstitial myo-
fibroblastic pool.
HSCs and tubulointerstitial remodeling
Tubuloepithelial turnover and healing. Tubular cell de-
differentiation and subsequent proliferation has been
considered the key, if not the only element, in the recov-
ery of the tubules epithelium from injury. However, re-
cent experimental and clinical data suggest a contribu-
tion from hematopoietic progenitor stem cells. As with
glomerular remodeling, tubuloepithelial injury has re-
cently been shown to be associated with an influx into the
kidneys of HSCs. This has been observed in experimental
models and in humans [62, 63] where bone marrow–
derived cells have been identified within regenerating
tubules. In a study based on the transplantation in mice
of male bone marrow into female recipients, in situ hy-
bridization to detect Y chromosomes demonstrated that
circulating stem cells frequently engraft into the kidney
and differentiate into renal parenchymal cells [63]. The
same authors showed a similar engraftment of recipient
male patients marrow cells into female renal allografts
[63]. In these allografts, the authors noted a variable
number of Y chromosome positive cortical tubular epi-
thelial cells. They also detected the presence of donor
male cells in the glomeruli and vascular endothelium. In
a model of ischemia/reperfusion injury in rats, we have
observed a significant infiltration of regenerating tubules
by CD34 cells (Ismail et al, unpublished observations,
2002). It is possible, however, that the expression of CD34
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in this study may be a manifestation of the de-differentia-
tion of injured tubuloepithelial cells into a embryonic
metanephric/mesenchymal phenotype (reverse embryo-
genesis). However, experiments relying on bone marrow
transplantation of male bone marrow into female rodents
with acute tubular necrosis showed that around 1% of
regenerating tubules contained Y chromosome cells [62].
When present, multiple cells in a positive tubule stained
for the Y chromosome [62]. These experiments clearly
demonstrate a role for bone marrow–derived stem cells
in tubules regeneration and turnover [62]. They also
show the capacity of these cells to acquire the mature
epithelial phenotype once engrafted into the regenerat-
ing kidney [62]. More recent data based on the injection
of HSCs expressing-galactosidase derived from Rosa26
transgenic male mice into female mice submitted to isch-
emic reperfusion renal injury showed -galactosidase
cells in the regenerating renal tubules [64]. They ap-
peared to localize primarily in renal proximal tubules and
expressed the male-specific Sry gene and Y chromosome.
Interestingly, some of these cells also expressed proximal
tubular transporters such as Na/Pi-2 [64]. They consti-
tuted around 8% of the cells in the regenerating kidney.
In view of their availability, HSC may offer an attractive
cell replacement therapy in acute tubular necrosis.
A role for HSCs in the repair of damaged organ has
been put forward [39, 65]. This has led to the question
of whether blood cells can turn into organ-specific, in-
cluding kidney, cells. Questions also arise as to how the
tissue conversion of an HSC takes place and how these
cells will assume the functional role of the organ into
which they have migrated. It has been argued that the
microenvironment (growth factors, ECM, and integrins)
of the organ in which these cells migrate influences the
maturation of the HSC into an organ-specific cell. It now
appears that the fusion of the HSCs with the resident
cells may be the answer with the formation of fused cells
with a chimeric genotype [65]. In fact, the genome of
the HSC is delivered into preexisting resident epithelial
cells. In the resultant hybrids, the tissue-specific mole-
cules dominate to activate resident cells genes and sup-
press those of the blood-derived cell [65]. Another ques-
tion pertains to the nature of the blood-derived cell that
fuses with the tissue-specific one. It has been suggested
that it may not be stem cells themselves that fuse but the
differentiated progeny of these cells such as circulating
macrophages [65]. However, the recent discovery of
multipotent adult progenitor cells (MAPCs) suggest that
these cells have the capacity to differentiate in vitro into
a variety of mature cells in isolation and without fusion
[66]. The source and nature of MAPCs remains a subject
of controversy and debate.
Interstitial fibrosis. Preliminary data from our labora-
tory and that of others [67] have also implied a contribu-
tion by bone-marrow-derived mesenchymal cells (MSCs)
to the renal interstitial fibroblastic pool. MSCs are mar-
row-derived progenitors of tissue fibroblasts and shuttle
through the circulation between the marrow and periph-
eral organs [39]. In a model of UUO, the transplantation
of Ly 5.1 mice with Ly 5.2 bone marrow demonstrated
the presence of Ly5.2 stem cells in the interstitium (Miya-
zaki et al, personal communication, 2001). These cells
expressed -SMA and collagen III suggesting their dif-
ferentiation into a myofibroblastic phenotype. The same
authors confirmed the bone marrow origin of these cells
(Y chromosome) by similar experiments in female UUO
mice transplanted by male bone marrow. In a study rely-
ing on the bone marrow transplantation of transgenic
FSP 1 GFP mice, the occasional FSP 1/GFP fibroblast
was noted in the renal interstitium of normal kidneys
[52]. The number of bone marrow–derived FSP 1/GFP
fibroblasts was increased in the interstitium of mice sub-
mitted to UUO and reached 15% of the fibroblastic
population [52]. A larger percentage of FSP 1 fibroblasts
observed in the UUO kidneys appeared to be derived
from local EMT [52]. The authors concluded that fibro-
genesis engaged two populations of fibroblastic cells, the
majority locally derived from EMT and a smaller per-
centage bone marrow–derived. Surprisingly, the FSP 1
bone marrow–derived fibroblasts detected in this study
were CD34 [52]. It was therefore postulated that either
the bone marrow–derived MSCs or endosteal bone mar-
row lining cells (BMLCs) may contribute to the pool of
renal fibroblasts [52]. Bone lining endosteum precedes
the formation of the bone marrow cavity and the CD34
BMLCs may transition into MSCs before their release
into the circulation and their subsequent differentiation
into renal fibroblasts [68].
Thus, marrow-derived stem cells, or their hematopoi-
etic progeny, along with quiescent renal interstitial fi-
broblasts, adventitia pericytes, and proximal tubular epi-
thelial cells, may all contribute to the pool of interstitial
myofibroblasts characteristic of interstitial kidney fibro-
sis (Fig. 2).
Therapeutic implications
A better understanding of the plasticity of renal cells
and their response to injury will allow us in the future
to manipulate such a response in order to promote heal-
ing and prevent scarring. It is becoming apparent that
EMT and the associated regression to an embryonic/
mesenchymal phenotype by mature kidney cells are asso-
ciated with a significant activation of intracellular signal-
ing pathways (reviewed in [50]). These, including Smads,
can be shown to be up-regulated in a variety of human
nephropathies [27–29]. Smad2 is activated during the fibro-
genic/EMT response of tubuloepithelial cells to TGF-1,
and this process is blocked by overexpression of Smad7
[69]. The overexpression of Smad7 in tubules epithelial
cells transfected with its gene leads to a marked inhibi-
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Fig. 2. Effect of bone marrow. Abbreviations are: MSC, marrow stro-
mal cells; HSC, hematopoietic cells; BMLC, bone marrow lining cells;
MC, mesenchymal cells; AC, adventitial cell (pericyte); TEC, tubuloepi-
thelial cells (proximal tubules cells); IF, interstitial renal fibroblasts;
MesC, mesangial cells; GEC, glomerular epithelial cell.
tion of TGF-1–induced Smad2 activation [69]. This is
associated with myofibroblast transformation and colla-
gen synthesis [69]. Thus, the inhibition of some of these
signaling pathways involving Smads (Smad2 and Smad3)
may prove promising therapeutic interventions for the
prevention EMT and the associated interstitial fibrosis.
The challenge will be to be able to differentiate appro-
priate from inappropriate EMT responses with the view
to encourage those judged physiologic and inhibit those
deemed pathologic.
The putative role of bone marrow–derived HSCs in
kidney remodeling may also have therapeutic implica-
tions. HSCs may have a therapeutic role to play in ac-
celerating the regenerative glomerular and tubular re-
sponses to injury. The challenge will consist of the source
and nature of injected cells as well as the timing of any
such intervention. Furthermore, research will be needed
to direct such injected cells to the kidney where they
would perform the requested task. In vitro and in vivo
manipulations of these cells may also contribute to their
therapeutic scope [45].
A better understanding of the role of bone marrow–
derived MSCs directly, or indirectly through BMLCs,
and other HSCs, in the pathogenesis of renal fibrosis
may also suggest new therapies aimed at its attenuation
and ultimately prevention.
CONCLUSION
The renal remodeling process is an extremely dynamic
process involving a constant differentiation and dediffer-
entiation of intrinsic renal cells as well as those infiltrat-
ing the damaged kidney. Embryogenesis seems to be
reversed in adult life as a way of rejuvenating injured
cells followed by its recapitulation to allow for the remat-
uration of these cells back into the adult phenotype.
Some renal cells, under pathologic conditions, fail to
bounce back from the embryonic phenotype into their
original mature one, but instead are transformed into
other cell lines. This process may be facilitated by the
pathologic environment, niche, thus guiding these cells
toward fibroblastic differentiation and fibrogenesis (Fig. 1).
Bone marrow–derived hematopoietic cells would be
equally guided by the renal microenvironment into bene-
ficial reconstituting epithelial phenotypes or harmful
fibroblastic ones (Fig. 1). Improved understanding of the
mechanisms regulating these processes may lead to more
innovative and original interventions favoring healing
and preventing scarring.
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